Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study-Reference-Cited by-同舟云学术

Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study

Published:2012-12-28 Issue:2 Volume:28 Page:151-159
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:

Author:

Mahé E.,Reguiai Z.,Barthelemy H.,Quiles-Tsimaratos N.,Chaby G.,Girard C.,Estève E.,Maccari F.,Descamps V.,Schmutz J.-L.,Begon E.,Bravard P.,Maillard H.,Boyé T.,Beauchet A.,Sigal M.-L.,

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.12066/fullpdf

Reference32 articles.

1. Pathogenesis and clinical features of psoriasis;Griffiths;Lancet,2007

2. Risk of myocardial infarction in patients with psoriasis;Gelfand;JAMA,2006

3. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis;Sommer;Arch Dermatol Res,2006

4. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis;Kaye;Br J Dermatol,2008

5. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis;Wolk;Acta Derm Venereol,2009

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The selection of the initial drug in the treatment of severe psoriasis;Meditsinskiy sovet = Medical Council;2023-09-27

2. Examining the influence of inflammatory bowel disease medications on sleep quality;JGH Open;2023-02-02

3. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities;BioDrugs;2023-01

4. Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study;Dermatology and Therapy;2022-08-11

5. Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr);Pediatric Drugs;2022-04-10